Burning Rock Q4 Revenues Down 4 Percent Due to COVID-19 Resurgence in China
The company's in-house test revenue dropped 16 percent and its hospital test kit sales fell 18 percent compared to Q4 2021.
In Brief This Week: Burning Rock Biotech, Biocartis, NYGC, Eagle Genomics, Theradiag, OpGen, More
News items for the week of Jan. 16, 2023.
In Brief This Week: Personalis, Burning Rock, Thermo Fisher, Caris Life Sciences, More
News items for the week of Jan. 3, 2023.
Burning Rock Biotech Q3 Revenues Climb 22 Percent
The company said in-hospital test sales have continued to grow, alongside it's newest MRD LDT, but COVID headwinds portend a leaner fourth quarter.
GenomeWeb Top 40 Declines 9 Percent in September, Marking Second Consecutive Down Month
The Dow Jones Industrial Average was down 9 percent, the Nasdaq was down 11 percent, and the Nasdaq Biotech Index was down around 2 percent.
May 31, 2022
Burning Rock Biotech Q1 Revenues up 27 Percent
Mar 22, 2022
Burning Rock Q4 Revenues up 12 Percent
Jan 3, 2022
GW Index Rises 3 Percent in December
Nov 17, 2021
Nov 16, 2021